Home > Healthcare > Pharmaceuticals > Finished Drug Form > Leuprolide Acetate Market

Leuprolide Acetate Market Share

Report ID: GMI5432
Published Date: Feb 2023
Report Format: PDF

Download Free Sample

Leuprolide Acetate Market Share

Dr. Reddy’s Laboratories Ltd.
Ferring B.V.
Varian Pharmed
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
BACHEM
Takeda Pharmaceutical Company Limited.
AbbVie Inc.
Merck & Co., Inc.
Beijing Biote Pharmaceutical Co., Ltd.
Taj Pharmaceuticals Limited.
Sayre Therapeutics
Livzon
Cipla Inc.
Anhui Anke Bioengineering (Group) Co., Ltd.
Bharat Serums and Vaccines Limited (BSV)
Zydus Group
Jagsonpal Pharmaceuticals Ltd.
Eugia

are some of the key players operating in the leuprolide acetate market.

These companies are primarily undertaking rigorous R&D programs and strategic collaborations with API manufacturers to expand their customer base and product portfolio, which is forecast to enhance the business scenario. For instance, in November 2022, Cipla Limited, an Indian pharmaceutical firm, introduced the U.S. FDA-approved Leuprolide Acetate Injection Depot 22.5mg. Used in the treatment of advanced prostate cancer, this product aided the firm in broadening its complex product range.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for leuprolide acetate was valued at more than USD 2 billion in 2022 and is set to progress at a 6% CAGR between 2023 and 2032 owing to the growing female population suffering from endometriosis and cancer as well as the soaring awareness regarding the benefits of leuprolide acetate injections.

The cancer application segment held more than 25% revenue share in 2022 and is projected to observe notable growth through 2032 due to the global rise in cancer cases which is increasing the demand for leuprolide acetate drugs for treatment.

The pre-filled syringes segment surpassed USD 910 million in revenue in 2022 as a result of rising consumer demand due to reduced patient risk and growing knowledge pertaining to the advantages of pre-filled syringes.

North America leuprolide acetate market held more than 39% market share in 2022 and is anticipated to record sizable progress over 2023-2032 on account of the favorable landscape for product approval from regulatory bodies, such as the U.S. FDA, in the region.